David Novak M.Sc.

David Novak joined the Lumira team in 2022 as a venture partner with a focus on developing public market investment strategies that leverage and build on the Lumira franchise. Mr. Novak brings to Lumira Ventures extensive capital markets, industry, and clinical research experience having served as a managing director at Raymond James, a large global investment dealer, where he covered the North American Biotechnology equities. In 2020, Mr. Novak was nominated as a “top 40 under 40” candidate by the Investment Industry of Canada. Additionally, he has been a leading source of biotechnology insight, appearing on CNBC, BNN/Bloomberg, CBC, and in various written media formats.

Before making his mark as a research analyst, Mr. Novak spent a number of years working on the scientific research side of the biotechnology industry, developing molecular diagnostic tests for oncology indications at a publicly-held company. Mr. Novak has additionally served as a clinical research scientist investigating both the hereditary predisposition to cancer as well as the experimental therapeutics which treat such cancers. His research has since culminated in multiple, high-impact publications within journals such as the New England Journal of Medicine.

David holds a Master of Science (Human Medical Genetics) from McGill University.